BLTE BELITE BIO INC

Belite Bio to Participate in the Leerink Partners Global Healthcare Conference

Belite Bio to Participate in the Leerink Partners Global Healthcare Conference

SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in the Leerink Partners Global Healthcare Conference being held on March 10-12, 2025, in Miami, FL. The Company will host a fireside chat on Monday, March 10, 2025, at 3:00 pm ET.

A webcast of the fireside chat can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: . The replay will be archived for 90 days following the presentation date.

About Belite Bio

Belite Bio is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases that have significant unmet medical needs such as Stargardt disease type 1, or STGD1 and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, and is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on , , , , or visit us at .

Media Relations Contact:

Jennifer Wu

Investor Relations Contact:

Julie Fallon



EN
04/03/2025

Underlying

BLTEBELITE BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BELITE BIO INC

 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Reports First Quarter 2025 Financial Results and Provides C...

Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update Following a pre-specified interim analysis, an independent Data Safety Monitoring Board (DSMB) recommended the pivotal Phase 3 trial (DRAGON) of Tinlarebant in adolescent Stargardt disease (STGD1) patients proceed without any modification; trial completion expected Q4 2025 (including a three-month follow-up period)DSMB also recommended the Company submit the interim data for further regulatory review for drug approvalA pivotal global Phase 3 trial (PHOENIX) of Tinlarebant in geographic atrophy (GA) patient...

May 14, 2025 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio to Participate in Four Upcoming Investor Conferences

Belite Bio to Participate in Four Upcoming Investor Conferences SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- , Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in four upcoming investor conferences. Details of the presentations are as follows: Deutsche Bank Depositary Receipts Virtual Investor Conference (Virtual) May 15, 2025, at 12:30 pm ET, corporate presentation H.C....

May 12, 2025 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2...

Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- , Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Wednesday, May 14, 2025, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the first quarter ended March 31, 2025. Webcast InformationDate: Wednesday, ...

May 7, 2025 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Announces Poster Presentations at the Association for Resea...

Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will give two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held May 4–8, 2025, in Salt Lake City, Utah. The presentations will hig...

April 29, 2025 1 EN
 PRESS RELEASE
Free
BLTE BELITE BIO INC

Belite Bio Announces Availability of Annual Report on Form 20-F Throug...

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company, today announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on March 17, 2025, is available through its website (). Shareholders may receive a hard copy of the annual report free of charge upon request. This press release is being...

March 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch